NEOS THERAPEUTICS,INC. (NASDAQ:NEOS) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On April27, 2018, Paul R. Edick resigned from the Board of Directors (the “Board”) of Neos Therapeutics,Inc. (the “Company”). Mr.Edick resigned to focus on other professional opportunities and his decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
On April27, 2018, the Board unanimously appointed Linda M. Szyper to the Board to fill the resulting vacancy. Upon her appointment to the Board, Ms.Szyper became a member of the class of directors with terms expiring at the 2018 Annual Meeting of Stockholders of the Company. The Board has determined that Ms.Szyper qualifies as an independent director and is qualified to serve under the applicable rulesand regulations of the Securities and Exchange Commission (the “SEC”) and the listing rulesof the Nasdaq Stock Market LLC. Ms.Syzper will serve as a member of the Company’s Compensation Committee and Nominating and Corporate Governance Committee. For her service on the Board, Ms.Szyper will receive the same compensation as other non-management directors, as described in the Company’s most recent proxy statement filed with the SEC. Ms.Szyper has also entered into the Company’s standard form of indemnification agreement.
Ms.Szyper, age 52, has been the Chief Operating Officer at McCann Health since January2018. From September2014 to March2017, Ms.Szyper was the Chief Commercial Officer and President, US Operations at Circassa Pharmaceuticals plc, or Circassa. Prior to joining Circassa, Ms.Szyper was the Chief Development Officer, PHCG Global Development of Publicis Healthcare Group from January2008 to September2014. Ms.Szyper holds a MBA from DePaul University’s Kellstadt Graduate School of Businessand a Bachelor of Science in biomedical engineering from Northwestern University.
There are no arrangements or understandings between Ms.Szyper and any other persons to which she was elected as a director of the Company. Ms.Szyper is the spouse of Mr.Edick, the former member of the Board. There are no other family relationships between Ms.Szyper and any director or executive officer of the Company, and she has no direct or indirect material interest in any transaction required to be disclosed to Item 404(a)of Regulation S-K. Ms.Szyper is qualified to serve on the Board based on her experience in product launch and commercialization in the pharmaceutical industry. Additionally, the Company believes it is important to increase the gender diversity of the Board by adding another female board member.
